InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,722.26
(
-0.19%
)
US TECH 100
19,517.20
(
0.53%
)
Dow Jones
41,914.75
(
-0.70%
)
Brent Oil
73.04
(
-0.20%
)
Bitcoin
62,850.01
(
-0.45%
)
Post# of 80490
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

zuize

Send PM Follow Ignore
Followers 6
Posts 461
Boards Moderated 0
Alias Born 11/13/2013

zuize

Re: gr8db8 post# 55375

Wednesday, 10/22/2014 7:17:52 PM

Wednesday, October 22, 2014 7:17:52 PM

Post# of 80490

AP26113 and Ponatinib saving lives. These are real stories, which may come out one day ...

Quotes like: I was on Crizotinib ... I was on Xalkori ... now AP26113 and then ... NED!

NO WAY does this company ever go BK. BO perhaps but never BK.



How much revenue Ap26113 would generate once it's approved by FDA??? I saw one of the post on YMB a few days ago mentioning that over 200,000 people in US alone diagnosed with lung cancer, in which 90% of the patients are NSCLC. And the average annual cost for treatment is around $60K/patient.
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up